Get the Stockscreener App
16.86
2.32%
-0.40
Tandem Diabetes Care Inc stock is traded at $16.86, with a volume of 1.13M.
It is down -2.32% in the last 24 hours and down -14.46% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$17.26
Open:
$17.1
24h Volume:
1.13M
Relative Volume:
0.74
Market Cap:
$1.13B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-8.067
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-1.06%
1M Performance:
-14.46%
6M Performance:
-51.57%
1Y Performance:
-46.90%
1-Day Range:
$16.53
$17.11
1-Week Range:
$16.30
$17.73
52-Week Range:
$15.75
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
16.86 | 1.13B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
When the Price of (TNDM) Talks, People Listen - news.stocktradersdaily.com
Reasons to Hold TNDM Stock in Your Portfolio for Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital Adjusts Tandem Diabetes (TNDM) Price Target Before Q - GuruFocus
RBC Cuts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Outperform Rating - marketscreener.com
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (LSE:0M0F) with Neutral Recommendation - Nasdaq
Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? - Yahoo Finance
Mizuho Initiates Coverage of Tandem Diabetes Care (TNDM) with Neutral Recommendation - Nasdaq
Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care - Benzinga
Mizuho Initiates Tandem Diabetes Care at Neutral With $20 Price Target - marketscreener.com
Mizuho sets Tandem Diabetes stock at Neutral with $20 target By Investing.com - Investing.com Canada
Mizuho Initiates Coverage of Tandem Diabetes (TNDM) with Neutral Rating | TNDM Stock News - GuruFocus
Tubeless Insulin Pump Market Set to Witness Significant Growth - openPR.com
SEC Form DEF 14A filed by Tandem Diabetes Care Inc. - Quantisnow
Diabetes Management Technologies Market Size, Report by 2034 - Precedence Research
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Tandem Diabetes Care stock hits 52-week low at $17.61 By Investing.com - Investing.com Australia
Tandem Diabetes Care To Announce First Quarter 2025 Financial Results - MarketScreener
Diabetes Tech Giant Tandem to Reveal Q1 Performance: Key Metrics Coming April 30 - Stock Titan
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Tandem Diabetes Care stock hits 52-week low at $17.61 - Investing.com
(TNDM) Investment Analysis - news.stocktradersdaily.com
Prudential Financial Inc. Purchases 39,784 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Tandem eyes Medicare coverage expansion for Type 2 - Yahoo Finance
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Artificial Pancreas Device System Market Projected To Witness - openPR
Tandem Diabetes Care Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution - simplywall.st
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.6% on Mar 26 - GuruFocus
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology - MSN
Stifel maintains Tandem Diabetes Care stock Buy rating, $60 target By Investing.com - Investing.com UK
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights - Investing.com
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Tandem announces publication of results from trial of Control-IQ+ AID technology - Yahoo Finance
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - Yahoo Finance
Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D - BioWorld MedTech
Tandem reports A1C reduction in type 2 diabetes study By Investing.com - Investing.com South Africa
Tandem Diabetes Launches Next-Gen Automated Insulin Delivery Algorithm in U.S. - MPO-mag
Tandem reports A1C reduction in type 2 diabetes study - Investing.com India
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
Automated Insulin Delivery System Helps in Type 2 Diabetes - Medscape
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery technology in the US - Marketscreener.com
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Enid News & Eagle
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):